n-acetylcystine
ApprovedSmall molecule
n-acetylcystine is one of 34 small molecule programs targeting Blood Transfusion. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1n-acetylcystine
UUniversity of California, San Francisco
Approved
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Celexa
AbbViePreclinical
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Symbicort
AstraZenecaPreclinical
Aciphex
Akero TherapeuticsPreclinical
Atrovent
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Blood Transfusion1 trial
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
Unknown status·—·Phase 1·NCT05777733·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for n-acetylcystine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details